Expertise in
2
conditions

Franz H. Schramel

St. Antonius Hospital
Nieuwegein, UT, NL 
Expertise in
2
conditions
St. Antonius Hospital
Nieuwegein, UT, NL 
OverviewLocationsClinical Research

Overview

Franz Schramel practices in Nieuwegein, Netherlands. Mr. Schramel is highly rated in 2 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Lung Metastases.

His clinical research consists of co-authoring 50 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

St. Antonius Hospital
Nieuwegein, UT 3435CM, Netherlands
Other Locations
Utrecht, UT 3584AA, Netherlands
Amersfoort, UT 3800BM, Netherlands
Onze Lieve Vrouwe Gasthuis
Amsterdam, NH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Chemotherapy in KRAS Mutated Chemotherapy Naive Non-small Cell Lung Cancer Patients: a Phase III Study Comparing Cisplatin-pemetrexed With Carboplatin-paclitaxel-bevacizumab: NVALT 22
Chemotherapy in KRAS Mutated Chemotherapy Naive Non-small Cell Lung Cancer Patients: a Phase III Study Comparing Cisplatin-pemetrexed With Carboplatin-paclitaxel-bevacizumab: NVALT 22
Enrollment Status: Unknown
Publish Date: December 21, 2021
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Bevacizumab, Pemetrexed, Cisplatin
Study Phase: Phase 3
A Randomized Phase III Study of Docetaxel Versus Intercalated Erlotinib Docetaxel Combination Therapy in Patients With Relapsed EGFR (Epidermal Growth Factor Receptor) Wild Type, ALK(Anaplastic Lymphoma Kinase) Negative Non Squamous Cell Carcinoma. (NVALT 18 Study)
A Randomized Phase III Study of Docetaxel Versus Intercalated Erlotinib Docetaxel Combination Therapy in Patients With Relapsed EGFR (Epidermal Growth Factor Receptor) Wild Type, ALK(Anaplastic Lymphoma Kinase) Negative Non Squamous Cell Carcinoma. (NVALT 18 Study)
Enrollment Status: Terminated
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

50 Total Publications

Silicosis Mimicking Lung Malignancy: A Case Series.
Silicosis Mimicking Lung Malignancy: A Case Series.
Journal: Respirology case reports
Published: May 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schramel's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile